Toll Free: 1-888-928-9744

Ewing Sarcoma - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 196 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ewing Sarcoma - Pipeline Review, H1 2016


Global Markets Direct's, 'Ewing Sarcoma - Pipeline Review, H1 2016', provides an overview of the Ewing Sarcoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Ewing Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Ewing Sarcoma
- The report reviews pipeline therapeutics for Ewing Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Ewing Sarcoma therapeutics and enlists all their major and minor projects
- The report assesses Ewing Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Ewing Sarcoma

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Ewing Sarcoma Overview 10 Therapeutics Development 11 Pipeline Products for Ewing Sarcoma - Overview 11 Pipeline Products for Ewing Sarcoma - Comparative Analysis 12 Ewing Sarcoma - Therapeutics under Development by Companies 13 Ewing Sarcoma - Therapeutics under Investigation by Universities/Institutes 15 Ewing Sarcoma - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Ewing Sarcoma - Products under Development by Companies 18 Ewing Sarcoma - Products under Investigation by Universities/Institutes 20 Ewing Sarcoma - Companies Involved in Therapeutics Development 21 Astellas Pharma Inc. 21 Cebiotex, S.L. 22 Celgene Corporation 23 EntreChem, S.L. 24 Exelixis, Inc. 25 Gradalis Inc. 26 Ipsen S.A. 27 Kolltan Pharmaceuticals, Inc. 28 Merck & Co., Inc. 29 Merrimack Pharmaceuticals, Inc. 30 NanoSmart Pharmaceuticals, Inc. 31 Nanovalent Pharmaceuticals Inc. 32 NantKwest, Inc. 33 Novartis AG 34 Oncomatryx Biopharma, S.L. 35 Recombio S.L 36 Shionogi & Co., Ltd. 37 Sigma-Tau S.p.A. 38 Tesaro, Inc. 39 Tokalas, Inc. 40 Ewing Sarcoma - Therapeutics Assessment 41 Assessment by Monotherapy Products 41 Assessment by Target 42 Assessment by Mechanism of Action 45 Assessment by Route of Administration 47 Assessment by Molecule Type 49 Drug Profiles 51 3BP-227 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 cabozantinib s-malate - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 CEB-01 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Cellular Immunotherapy for Oncology - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 celyvir - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 EC-8042 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 EC-8105 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 everolimus - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 gemogenovatucel-T - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 haNK Program - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 irinotecan hydrochloride - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 KIT-SG3227 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 linsitinib - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Monoclonal Antibody Conjugate 1 for Ewing Sarcoma - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 niraparib - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 NV-101 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 OMTX-503 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 OMTX-703 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 paclitaxel albumin bound - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 pazopanib hydrochloride - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 pembrolizumab - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 racotumomab - Drug Profile 113 Product Description 113 Mechanism of Action 113 R&D Progress 113 RNAi Gene Therapy to Inhibit EWS and FLI1 for Ewing Sarcoma - Drug Profile 115 Product Description 115 Mechanism of Action 115 R&D Progress 115 roneparstat - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 S-588410 - Drug Profile 117 Product Description 117 Mechanism of Action 117 R&D Progress 117 Small Molecules for Ewing Sarcoma - Drug Profile 119 Product Description 119 Mechanism of Action 119 R&D Progress 119 SP-2509 - Drug Profile 120 Product Description 120 Mechanism of Action 120 R&D Progress 120 SP-2528 - Drug Profile 122 Product Description 122 Mechanism of Action 122 R&D Progress 122 SP-2577 - Drug Profile 123 Product Description 123 Mechanism of Action 123 R&D Progress 123 TK-216 - Drug Profile 124 Product Description 124 Mechanism of Action 124 R&D Progress 124 YK-4279 - Drug Profile 125 Product Description 125 Mechanism of Action 125 R&D Progress 125 Ewing Sarcoma - Recent Pipeline Updates 127 Ewing Sarcoma - Dormant Projects 189 Ewing Sarcoma - Discontinued Products 190 Ewing Sarcoma - Product Development Milestones 191 Featured News & Press Releases 191 Oct 09, 2015: Novel compound turns off mutant cancer gene in animals with leukemia 191 Jul 30, 2015: NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 191 Jun 04, 2015: Gradalis Announces Presentation of Data From a Pilot Study of Vigil Cancer Vaccine in Ewing's Sarcoma 192 Feb 11, 2015: NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing's Sarcoma 192 Nov 26, 2012: Possible New Treatment for a Childhood Cancer 193 Apr 16, 2012: EntreChem's Mithramycin Analog EC-8042 Shows Increased Potency And High Selectivity For Treatment Of Sarcoma 194 Apr 16, 2012: EntreChem's Mithramycin Shows Increased Potency And Higher Selectivity For Treatment Of Sarcoma 194 Appendix 195 Methodology 195 Coverage 195 Secondary Research 195 Primary Research 195 Expert Panel Validation 195 Contact Us 195 Disclaimer 196
List of Tables
Number of Products under Development for Ewing Sarcoma, H1 2016 11 Number of Products under Development for Ewing Sarcoma - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Products under Investigation by Universities/Institutes, H1 2016 20 Ewing Sarcoma - Pipeline by Astellas Pharma Inc., H1 2016 21 Ewing Sarcoma - Pipeline by Cebiotex, S.L., H1 2016 22 Ewing Sarcoma - Pipeline by Celgene Corporation, H1 2016 23 Ewing Sarcoma - Pipeline by EntreChem, S.L., H1 2016 24 Ewing Sarcoma - Pipeline by Exelixis, Inc., H1 2016 25 Ewing Sarcoma - Pipeline by Gradalis Inc., H1 2016 26 Ewing Sarcoma - Pipeline by Ipsen S.A., H1 2016 27 Ewing Sarcoma - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016 28 Ewing Sarcoma - Pipeline by Merck & Co., Inc., H1 2016 29 Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 30 Ewing Sarcoma - Pipeline by NanoSmart Pharmaceuticals, Inc., H1 2016 31 Ewing Sarcoma - Pipeline by Nanovalent Pharmaceuticals Inc., H1 2016 32 Ewing Sarcoma - Pipeline by NantKwest, Inc., H1 2016 33 Ewing Sarcoma - Pipeline by Novartis AG, H1 2016 34 Ewing Sarcoma - Pipeline by Oncomatryx Biopharma, S.L., H1 2016 35 Ewing Sarcoma - Pipeline by Recombio S.L, H1 2016 36 Ewing Sarcoma - Pipeline by Shionogi & Co., Ltd., H1 2016 37 Ewing Sarcoma - Pipeline by Sigma-Tau S.p.A., H1 2016 38 Ewing Sarcoma - Pipeline by Tesaro, Inc., H1 2016 39 Ewing Sarcoma - Pipeline by Tokalas, Inc., H1 2016 40 Assessment by Monotherapy Products, H1 2016 41 Number of Products by Stage and Target, H1 2016 43 Number of Products by Stage and Mechanism of Action, H1 2016 46 Number of Products by Stage and Route of Administration, H1 2016 48 Number of Products by Stage and Molecule Type, H1 2016 50 Ewing Sarcoma Therapeutics - Recent Pipeline Updates, H1 2016 127 Ewing Sarcoma - Dormant Projects, H1 2016 189 Ewing Sarcoma - Discontinued Products, H1 2016 190

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demand


Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is ant


Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliab


Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to mo


Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period


To learn more about this report, request a free sample copy

Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.